May 21, 2018 / 7:33 PM / a month ago

BRIEF-Sesen Bio Reports Positive 3-Mth Data From VISTA Trial of Vicinium in High-Grade NMIBC

May 21 (Reuters) - Sesen Bio Inc:

* PHASE 3 REGISTRATION TRIAL FOR NON-MUSCLE INVASIVE BLADDER CANCER ACHIEVES 42% COMPLETE RESPONSE RATE AT THREE MONTHS IN CARCINOMA IN SITU PATIENTS

* TO DATE, VICINIUM HAS BEEN WELL-TOLERATED IN VISTA TRIAL

* Reports Positive, Three-Month Data From VISTA Trial of Vicinium In High-Grade NMIBC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below